Skip to main content

Dr. Moises A. Issa, M.D.

Internal Medicine (Internal Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
29
In the NPI registry since
2005
Medicare patients seen, 2024
63

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Internal Medicine Physician primary
    FL license ME81676

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Internal Medicine per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
63
Services billed
922
Patients’ average age
73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 32 companies reported 113 payments worth $4,349 in total to this clinician.

By type
Food and Beverage$2,663
Travel and Lodging$1,686

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 23, 2025Amgen Inc.
Jul 23, 2025
Travel and Lodging
travel to Dallas, TX · in-kind
$655
Jul 23, 2025Amgen Inc.
Jul 23, 2025
Travel and Lodging
travel to DALLAS, TX · in-kind
$575
Jul 23, 2025Amgen Inc.
Jul 23, 2025
Travel and Lodging
travel to Dallas, TX · in-kind
$375
Jul 25, 2025Amgen Inc.
Jul 25, 2025
Travel and Lodging
travel to Dallas, TX · in-kind
$81.25

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $736,932 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or O…
    Amgen Inc.
  • A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
    Novartis Pharmaceuticals Corporation
  • A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
    Novartis Pharmaceuticals Corporation
  • Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
    Novartis Pharmaceuticals Corporation
  • A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
    Novartis Pharmaceuticals Corporation
  • A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
    AstraZeneca Pharmaceuticals LP
  • A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
    Novartis Pharmaceuticals Corporation
  • SUBLOCADE Long-term Outcomes
    Indivior Inc. · Completed · NCT05860959

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Hollywood

Sources

NPI registry (CMS NPPES, November 2026; record last updated December 6, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1558357780. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.